These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25848212)

  • 21.
    Zhang J; Huang J; He X; Li N; Miao Y; Li B; Shao X; Wang N
    Gynecol Endocrinol; 2022 Apr; 38(4):318-323. PubMed ID: 35285758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists.
    Ferrero H; García-Pascual CM; Gaytán M; Morales C; Simón C; Gaytán F; Pellicer A; Gómez R
    Fertil Steril; 2014 Nov; 102(5):1468-1476.e1. PubMed ID: 25217874
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Zhang J; Huang J; He X; Li N; Miao Y; Li B; Shao X; Wang N
    Gynecol Endocrinol; 2022 Feb; 38(2):170-175. PubMed ID: 34964405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian hyperstimulation syndrome-model rats; the manifestation and clinical implication.
    Ohba T; Ujioka T; Ishikawa K; Tanaka N; Okamura H
    Mol Cell Endocrinol; 2003 Apr; 202(1-2):47-52. PubMed ID: 12770729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    BJOG; 2014 Jun; 121(7):848-55. PubMed ID: 24621101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model.
    Engin-Ustun Y; Yılmaz S; Timur H; Ustun Y; Moraloglu O; Deveer R; Yılmaz N
    Gynecol Endocrinol; 2013 Sep; 29(9):851-4. PubMed ID: 23862585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats.
    Gómez R; Lima I; Simón C; Pellicer A
    Reproduction; 2004 Apr; 127(4):483-9. PubMed ID: 15047939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
    van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
    Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical detection of transforming growth factor-alpha, epidermal growth factor, and vascular endothelial growth factor expression in hyperstimulated rat ovary.
    Ozcakir HT; Giray SG; Ozbilgin MK; Uyar Y; Lacin S; Caglar H
    Acta Obstet Gynecol Scand; 2005 Sep; 84(9):887-93. PubMed ID: 16097982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade.
    Gómez R; Simón C; Remohí J; Pellicer A
    Endocrinology; 2002 Nov; 143(11):4339-48. PubMed ID: 12399430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can a cyclooxygenase inhibitor be an option for treatment of ovarian hyperstimulation syndrome?
    Çilgin H
    Drug Des Devel Ther; 2019; 13():1099-1105. PubMed ID: 31040646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome.
    Agrawal R; Tan SL; Wild S; Sladkevicius P; Engmann L; Payne N; Bekir J; Campbell S; Conway G; Jacobs H
    Fertil Steril; 1999 Feb; 71(2):287-93. PubMed ID: 9988400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
    Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
    Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Function of vascular endothelial growth factor in ovarian hyperstimulation syndrome].
    Liang W; Chen S; Xing F
    Zhonghua Fu Chan Ke Za Zhi; 2001 Nov; 36(11):651-3. PubMed ID: 11930687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Relationship between letrozole administration during the luteal phase after oocyte retrieval and the early-stage ovarian hyperstimulation syndrome oocurrence].
    He Q; Xu J; Cui S; Li H; Zhang C
    Zhonghua Fu Chan Ke Za Zhi; 2014 Dec; 49(12):909-13. PubMed ID: 25608991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized study.
    Kitsou C; Kosmas I; Lazaros L; Hatzi E; Euaggelou A; Mynbaev O; Tournaye H; Prapas N; Prapas I; Zikopoulos K; Galani V; Georgiou I
    Gynecol Endocrinol; 2014 Aug; 30(8):587-92. PubMed ID: 24819316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of formoterol on the serum, peritoneal VEGF, MDA, and VEGF levels in the ovaries and endometrium of rats with OHSS.
    Inal HA; Ozturk Inal ZH; Yilmaz N; Timur H; Oruc AS; Kalem MN; Han O
    Clin Exp Obstet Gynecol; 2017; 44(1):122-128. PubMed ID: 29714880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
    Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
    Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.